Extracellular domain of HER2: a useful marker for the initial workup and follow-up of HER2-positive breast cancer.

Abstract

ECD-HER2 is a reliable marker for breast cancer, as suggested from the existing literature; therefore, its integration in the initial workup and follow-up routine of breast cancer, particularly the HER2-positive, is proposed.